How would you manage active non-stricturing, non-fistulizing moderate ileal Crohn’s disease in patients on Natalizumab with well-managed multiple sclerosis?
Do you consider combination therapy and if so, which agent?
Answer from: at Academic Institution
I would be hesitant to add a second immunosuppressing medication to natalizumab. I might consider vedolizumab given a favorable safety profile (even though evidence suggests it is less effective for ileal disease) or talk with a Neurologist about switching from NAT to another drug for MS that might ...
Comments
at Icahn School of Medicine at Mount Sinai I share Dr. @Pardi’s caution but not his hes...
I share Dr. @Pardi’s caution but not his hes...